Advanced Proteome Therapeutics Corp.

Advanced Proteome Therapeutics Proposes Share Consolidation

Vancouver, British Columbia / April 24, 2019 – Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), announces that management has determined that it is in the best interests of the Company and its shareholders to consolidate the issued common shares of the Company on the basis of one new share for every ten existing shares. The Board of Directors has determined that the consolidation is necessary in order to finance the company’s continued operations.

The completion of the share consolidation is subject to stock exchange approval. The name of the Company will remain unchanged. The Company’s current issued capital is 166,980,999 common shares. Upon completion of the share consolidation, the Company’s issued capital would become an estimated 16,698,999 common shares.

ABOUT THE COMPANY:

Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., has invented proprietary protein conjugation technology which enables the development of superior antibody-drug conjugates through improved site-specific labeling, drug-antibody ratio control and enabling of combination payloads. The technology has compelling pre-clinical data demonstrating improved homogeneity and increased in-vivo potency relative to current state of the art linker technology. The Company believes that the technology will enable the development of safer and more potent antibody-drug conjugate therapeutics and is pursuing licensing and partnership opportunities to advance development and create shareholder value.

FOR FURTHER INFORMATION PLEASE CONTACT:

Advanced Proteome Therapeutics Corporation

Paul Woodward

President and CEO

Tel: 604 690-3797

http://www.advancedproteome.com